Analysts: Gilead Estimates Raised Following Initial Drug Pricing and 3 More Research Notes to Read
Gilead Sciences Inc. (NASDAQ:GILD): Bank of America Merrill Lynch raised its Buy-rated Gilead HCV estimates based on the initial SOF gross pricing of $95,000 and a peak sales estimate of approximately $10 billion; the firm raised its 2014-2018 estimates by 30-48 percent and its price target to $107 from $96.
Tile Shop Holdigs Inc. (NASDAQ:TTS): R.W. Baird lowered its price target on Tile Shop to $24 from $30 following meetings with management, citing concerns over internal controls as well as lingering uncertainties that will impair the company’s valuation multiple. However, Baird feels Tile Shop’s fundamental story remains intact and maintains its Outperform rating.
Marvell Technology Group Ltd. (NASDAQ:MRVL): Brean Capital noted that Marvell’s third-quarter results were its fourth consecutive quarter to beat estimates. The firm raised its estimates and price target on the stock to reflect the company’s success at turning around the Mobile and Wireless business; its price target on Marvell Technology shares is $17, up from $16, and the analyst pegs a Buy rating on the name.
Splunk Inc. (NASDAQ:SPLK): Susquehanna raised its price target on Splunk following its strong third-quarter results, to $74 from $67; the firm cited the company’s licensing growth, increased demand for its operational intelligence platform, contracts that will build recurring revenue streams, and a broadening of its core Machine Data Analytics platform. The firm rates Splunk shares as Positive.